To determine whether aspirin or aspirin + dipyridamole would produce a significant reduction in the subsequent occurrence of fatal and nonfatal cerebral infarction.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
Randomized, double-blind, placebo-controlled trial of 604 patients.
Patients were randomized into one of three groups: A-aspirin (1 g/day); AD-aspirin (1 g/day) + dipyridamole (225 mg/day); P-placebo. Follow-up period of 3 years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Recurrence of fatal or nonfatal cerebral infarction within 3 years.|